English
Polski
Español
українська
Capillaroscopy in Raynaud phenomenon
Should we perform capillaroscopy in every patient with Raynaud phenomenon?
2024-01-16
Should we perform capillaroscopy in every patient with Raynaud phenomenon?
What is the risk of a systemic connective tissue disease in persons with Raynaud phenomenon? Does the prognostic value of Raynaud phenomenon differ between women and men?
Should febuxostat be contraindicated in patients with cardiovascular disease? Can it be used as the drug of choice (instead of allopurinol) in long-term gout treatment?
What manifestations of giant cell arteritis are associated with a high risk of vision loss?
Should we treat hyperuricemia without clinically relevant gout?
How does the treatment of primary Raynaud phenomenon differ from that in Raynaud phenomenon secondary, for example, to systemic sclerosis?
What to pay attention to in patients with Raynaud phenomenon? Which diagnostic tests should be routinely performed?
What disorders other than connective tissue diseases can be the cause of Raynaud phenomenon?
In view of recent clinical trials, which patients with SLE may benefit most from treatment with a type 1 interferon antagonist? Is the safety profile of this therapy acceptable today, in the era of the mutating SARS-CoV-2 pandemic?
What abnormalities in laboratory test results of a patient with newly diagnosed SLE should be most alarming?
